In line with these findings, a recent neurophysiological study in a combined amyloid and tau mouse model showed decreased gamma power compared to amyloid-only models [98], which fits recent data indicating decreased frontal gamma activity in human AD dementia patients [9]. The gene discussed is MAPT; the disease is Alzheimer disease.